Imatinib Onkovis

Imatinib, the active ingredient in Imatinib Onkovis, is a tyrosine kinase inhibitor presented as an oral formulation for oral use. It treats chronic myeloid leukemia, Philadelphia chromosome‑positive acute lymphoblastic leukemia, and gastrointestinal stromal tumor in appropriate patients.

GNH USA supplies Imatinib Onkovis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Imatinib acts on malignant cells driven by BCR‑ABL, c‑KIT or PDGFR tyrosine‑kinase signaling pathways. It is indicated for: - Chronic myeloid leukemia (CML): reduces leukemic cell proliferation and improves long‑term survival. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): achieves remission by targeting BCR‑ABL‑positive blasts. - Gastrointestinal stromal tumor (GIST): inhibits c‑KIT‑driven tumor growth and delays disease progression.

Imatinib may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Edema: peripheral swelling, especially of the ankles. - Fatigue: generalized tiredness. - Diarrhea: loose stools. - Muscle cramps: occasional involuntary contractions. - Rash: mild skin irritation.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or liver injury. - Cardiotoxicity: heart failure or reduced left‑ventricular function. - Severe neutropenia: marked decrease in white blood cells. - Hemorrhage: bleeding tendencies. - Pulmonary arterial hypertension: increased pressure in lung arteries. - Anaphylaxis: rare severe allergic reaction.

Before initiating therapy, clinicians should assess baseline organ function and monitor patients regularly. - Hepatic function: evaluate liver enzymes and adjust use in hepatic impairment. - Cardiac assessment: perform baseline cardiac evaluation in patients with pre‑existing heart disease. - Hematologic monitoring: conduct regular CBC to detect neutropenia or anemia. - Pregnancy risk: avoid use during pregnancy unless benefits outweigh risks; discuss contraception. - Breastfeeding: do not breastfeed while receiving treatment. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture and direct sunlight.

Imatinib interacts with several drugs that can alter its plasma concentration or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise imatinib levels and risk severe toxicity. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): can lower imatinib exposure, reducing efficacy.

Moderate Interactions (Monitor Closely): - Acid‑reducing agents (e.g., proton pump inhibitors, antacids): may affect absorption; monitor therapeutic response. - Concomitant anticoagulants (e.g., warfarin): increased bleeding risk; check coagulation parameters. - Vaccines (live attenuated): potential reduced vaccine efficacy; consider timing of administration.